mXELIRI could be practice-changing by providing an alternative to irinotecan-based regimens for some patients, but may not work in non-Asian populations.
A highly selective small molecule A3AR agonist blocked development of oxaliplatin-induced neuropathic pain without interfering with anticancer effects.
Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer.
Given disconcerting low success rates overall in immunotherapy, some leading oncologists are calling for greater scientific rigor in clinical trial design.
Pooled data show PET imaging of metabolic tumor burden at diagnosis helps identify patients most at risk of FL recurrence.
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.
Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.
Take our latest quiz to learn about differences in MM incidence, complications, and treatment among men, women, and various racial and ethnic groups.
A large prospective analysis of data from the UK Women’s Cohort Study found an association between red meat consumption and distal colon disease risk.
A multicenter team of researchers reports that JAK3/STAT5 mutations are important in ALL and may be targetable.
The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.
The combination of the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib yielded improved progression-free survival over vemurafenib in patients with advanced BRAF V600–mutant melanoma.
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination.
The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non–small-cell lung cancer.